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ORIGINAL ARTICLE

Reconstructive
Use of Native Type I Collagen Matrix Plus
Polyhexamethylene Biguanide for Chronic
Wound Treatment
Alisha R. Oropallo, MD, FACS*†

Background: Chronic wounds represent a significant financial burden to the
healthcare system and a quality-of-life burden to patients. Many chronic wounds
have elevated bioburden in the form of biofilm, which has been associated with
delayed wound healing. This study examined the use of a native type I collagen matrix with the antimicrobial polyhexamethylene biguanide (PCMP) in the management of bioburden and treatment of chronic, nonhealing wounds over 12 weeks.
Methods: A prospective case series of PCMP enrolled adults ≥18 years old with a
nonhealing wound. At week 0, the wound was prepared by sharp or mechanical
debridement. Patients received standard wound care plus PCMP applications at
week 0 and then weekly up to week 12 at the investigator’s discretion. Dressings
were applied over PCMP to fix it in place. At each visit, wounds were assessed for
the extent of healing and signs of wound infection.
Results: Of the 41 wounds studied, 44% were pressure ulcers, 22% were surgical
wounds, 12% were venous ulcers, 10% were diabetic ulcers, and 12% were another
type. The median (interquartile range) baseline wound area was 7.2 (14.9) cm2,
and the mean wound duration was 103 weeks. Of the 41 wounds, 73% demonstrated a reduction in wound area at 12 weeks, and 37% achieved complete wound
closure, with a mean time of 6.7 weeks to complete closure.
Conclusion: PCMP treatment appeared to positively impact the course of
wound healing in a variety of complex, chronic wounds that were unresponsive to prior treatment. (Plast Reconstr Surg Glob Open 2019;7:e2047; doi: 10.1097/
GOX.0000000000002047; Published online 15 January 2019.)

INTRODUCTION

Chronic wounds are characterized by repeated tissue
injury, ischemia, and elevated bacterial burden, all of which
combine to result in continued inflammation and an imbalance in tissue proteases and inhibitors.1–3 Chronic wounds,
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The elevated bioburden in chronic wounds is often
in the form of biofilm.11 Biofilm occurs when planktonic
(free-floating) bacteria adhere to a solid surface, proliferate, and exude substances to form a polymeric matrix
enclosing a monomicrobial or polymicrobial community.12,13 Approximately 10–20% of the biofilm is composed
of microorganisms and 80–90% is composed of extracellular polymeric matrix.14 In 2010, there were an estimated
17 million biofilm-associated disease cases in the United
States, with direct costs of approximately $94 billion.15
Chronic wounds with a large quantity of slough may be at
an increased risk of developing pathogenic and antimicrobial-resistant biofilms.14 Emerging evidence indicates that
the presence of biofilm is associated with delayed wound
healing.16–18 Compared with planktonic bacteria, bacteria
in biofilms are more difficult to eradicate using topical or
systemic antibiotics.13,19,20
Debridement of a chronic wound is the first step to
disrupting a pathogenic biofilm and removing necrotic
tissue, both of which contribute to delayed wound healing.14,21 However, debridement is not sufficient by itself.
Recent research has shown that clinic-based debridement
of chronic ulcers has minimal effect on surface bacterial
counts.22 Topical antiseptics and antimicrobials can be applied after debridement to reduce the bacterial count and
assist in wound healing.23,24 Historical options for wound
antimicrobial treatment include silver, honey, iodine, or
chlorhexidine. However, questions remain about the efficacy and safety of these agents when they are applied in
dressings.24,25
Polyhexamethylene biguanide hydrochloride (PHMB)
is a cationic topical antimicrobial that strongly binds to bacterial cell walls and membranes, disrupting the transport,
biosynthesis, and catabolic functions of the bacterium.26,27
PHMB possesses broad antimicrobial activity against
Gram-positive and Gram-negative bacteria, plaque- and
biofilm-forming bacteria, and intracellular bacteria such as
Chlamydiae and Mycoplasma.27 In addition, PHMB binds to
biofilm matrix components and increases in concentration
during application, thereby creating an increasingly toxic
environment for bacteria.28 PHMB does not seem to be affected by multidrug efflux pumps or acquired resistance
developed by bacteria.26,27 It is regarded as a very biocompatible antiseptic that shows little-to-no toxicity or systemic
uptake when applied on intact skin or wounds.27,29 A recent
systematic review demonstrated that use of PHMB dressings
was associated with faster and more substantial reductions
in bacterial counts, including multidrug-resistant species,
than control dressings.30 A study of PHMB dressings used in
wounds with biofilm showed positive outcomes for wound
disinfection and patient-reported pain.31
Collagen matrices can serve as a sacrificial surface for
matrix metalloproteinases and elastase that are prevalent
in chronic wounds, thus protecting tissue collagen deposition.32 Retaining the native collagen matrix structure supports healing and has been shown to effectively address
the protease imbalance seen in chronic wounds, and support granulation tissue formation and epithelialization.33
Collagen matrices can sequester proteolytic enzymes and
act as a biocompatible scaffold to support healing.34
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Here, we propose using native type I porcine-derived
collagen matrix coated with 0.1% PHMB (porcine collagen matrix with PHMB, further referenced as PCMP).
PCMP is a Food and Drug Administration Class II Medical Device 510(k) cleared #K051647 and intended for the
management of wounds, as an effective barrier to resist
microbial colonization within the dressing and reduce
microbes penetrating through the dressing. PCMP is the
only dressing available in the United States with the combination of native collagen matrix and PHMB. It is supplied dry in sheet form and packaged in sterile, sealed
single patches.35
The aim of this study was to assess the ability of PCMP
to meet wound-specific treatment goals including management of bioburden, support of granulation tissue formation, and support of wound closure over a 12-week period
in chronic, nonhealing wounds of various etiologies.

METHODS
Study Design

A single-center, prospective, case series of PCMP (PuraPly Antimicrobial, Organogenesis Inc., Canton, Mass.) was
conducted (NCT03070925). The study was approved by
Biomedical Research Alliance of New York, IRB #16-08209-03, and was conducted in accordance with current
International Council for Harmonisation and Good Clinical Practice guidelines. All patients provided their written informed consent to participate in the study. Eligible
wounds were evaluated weekly for up to 12 weeks for size,
healing, and improvement in granulation tissue.
Participants

Adults ≥18 years of age with at least 1 appropriate
wound (including partial- and full-thickness wounds, pressure ulcers, venous leg ulcers, diabetic foot ulcers, chronic
vascular ulcers, surgical wounds, or trauma wounds) were
eligible for inclusion. Individuals were excluded from participating if they were receiving concurrent treatment with
other topical antimicrobials or skin substitute products, or
if they had a third-degree burn or a known sensitivity to
any of the PCMP materials.
Procedures

Eligible patients with an identified target wound underwent clinical assessments and received standard of care as
determined by the treating physician. The treating physician determined the frequency and type of assessments performed for each patient, according to standard of care for
their target wound and the patient’s individualized needs
for treatment and follow-up. Data were collected at every
clinical visit in which PCMP was applied to the target wound
and at postapplication follow-up visits as appropriate.
Wounds were cleaned and prepared with sharp debridement or mechanical debridement at the initial visit.
After preparation, PCMP was applied at week 0 to the
study wound. Each PCMP sheet was on the wound for a
minimum of 1 week and a maximum of 3 weeks. In moist
wounds, when PCMP was applied; no saline was needed
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to moisten the product. It was fixated with nonadherent
dressing (CONFORMANT 2; Smith & Nephew, Largo,
Fla.) and secured at the edges with steri-strips or strips
of retention dressing (Hypafix; Smith & Nephew). The
nonadherent dressing allowed the wound to drain. Foam
dressing (Allevyn; Smith & Nephew) was placed over the
nonadherent dressing. Gauze and stretch bandage were
applied to fix all the dressings in place. For drier wounds,
saline-moistened PCMP was covered with nonadherent
dressing, and secured at the edges with steri-strips or strips
of retention dressing. Gauze and stretch bandage were applied to fix the dressings and PCMP in place. The outer
dressings could be changed within 1 week, if needed, without disturbing the PCMP and the nonadherent dressing.
Assessments

At each clinic visit, wounds were assessed for the extent
of healing and any signs of wound infection. Wound measurements included wound area and depth, and achievement of complete wound closure (Yes/No). Photographs
were taken before PCMP application, before removal of
the PCMP, after debridement, after placement of a new
PCMP, and, if it occurred, upon healing.
Statistical Analysis

All analyses were performed on patients who received
PCMP treatment (intent-to-treat population). Descriptive
statistics (eg, mean, SD, median) were calculated with
Microsoft Excel 2016 (version 16.0.9330.2124) for demographic and baseline characteristics, the time to wound
closure, the change in wound surface area from baseline
to week 12, and the percent wound closure from baseline to week 4 or 12. The Wilcoxon signed rank test was
performed (Microsoft Excel 2016) to examine whether
the wound area at week 12 was significantly different (at
α = 0.05) from the baseline area. No patient showed signs
of complications or infection at the conclusion of the
study.

RESULTS

A total of 41 wounds (1 wound per participant) were
included in the analysis. The mean (SD) age of participants was 61.9 (14.1) years and 65.9% (27/41) were male
Table 1. Demographic and Baseline Characteristics
Characteristics
Age (y), mean (SD)
Sex, n (%)
 Female
 Male
Race, n (%)
 White
 Black
 Asian
 Other
Baseline wound area (cm2), mean (SD)
Median
Range
Baseline wound depth (mm), mean (SD)
ITT, intent-to-treat.

ITT Population
(n = 41)
61.9 (14.1)
14 (34.1)
27 (65.9)
27 (65.9)
5 (12.2)
2 (4.9)
7 (17)
18.0 (36.1)
7.2
0.3, 218.5
0.58 (0.64)

(Table 1). At baseline, 18 of 41 (43.9%) of the wounds
were pressure ulcers, 9/41 (22.0%) were surgical wounds,
5/41 (12.2%) were venous leg ulcers, 4/41 (9.8%) were
diabetic foot ulcers, and 5/41 (12.2%) were another type
of wound. The median (interquartile range) baseline
wound area was 7.2 (14.9) cm2, and the mean (SD) depth
was 0.58 (0.64) mm. The mean wound duration before
PCMP application was 103.1 weeks (n = 41).
The anatomical locations of patient wounds varied.
Wounds were located on the foot (n = 19), ankle (n = 5),
anterior leg (n = 5), toe (n = 3), heel (n = 2), sacrum
(n = 2), ischium (n = 2), and 1 each on the thigh, breast,
knee, and posterior leg.
There was a vast array of comorbidities present within
the cohort; however, certain ailments were represented
heavily. Hypertension was present in 28 patients, type 2
diabetes mellitus in 22, hyperlipidemia in 15, peripheral
vascular disease in 13, coronary artery disease in 11, and
chronic kidney disease in 9 patients.
Before participating in the study, 16 (38.1%) patients
underwent compression therapy, 27 (64.3%) had attempted off-loading, 42 (97.7%) patients had the target
wound debrided at least once before starting the study,
10 (23.8%) patients used negative pressure therapy, 10
(23.8%) underwent hyperbaric oxygen therapy, 7 (17.1%)
patients had an amputation performed due their wound,
7 (17.1%) attempted surgical closure of their wounds, 12
(29.3%) patients were treated with skin substitutes, and
13 (34.2%) used topical antimicrobials on their wounds.
PCMP is typically applied on a weekly basis according
to standard of care and the patient’s individualized needs
for treatment and follow-up. For a few patients in this
study, PCMP was left in place for 2–3 weeks. At the week
1 follow-up visit after PCMP application, the usual course
of action is to remove the PCMP and reapply. However,
in these few patients, the PCMP was found to be dry and
stuck to the wound at the follow-up. Rather than remove
the PCMP and potentially open the wound, the PCMP was
left in place until a subsequent visit, at which point it had
either integrated into the wound or could lift off easily,
revealing a healed wound.
The 41 wounds in this study received an average of 8
PCMP applications each. During this study, 2/41 patients
received adjunctive therapy of hyperbaric oxygen treatments; both patients had pressure ulcers that had been
present for over 1 year before study entry and had prior
hyperbaric oxygen treatments for the study wound. Of the
41 wounds, 30 (73.2%) demonstrated an overall reduction
in wound area over the 12-week study and 15/41 (36.6%)
achieved complete wound closure (Fig. 1). Of the wounds
achieving complete closure, the mean (SD) time to closure
was 6.7 (3.0) weeks. By wound type, 7/18 (38.9%) of pressure ulcers, 5/9 (55.6%) of surgical wounds, 1/1 (100%)
of trauma wounds, 1/4 (25%) of diabetic foot ulcers,
and 1/5 (20%) of venous leg ulcers achieved complete
closure. Mean wound closure by wound type is shown in
Table 2. Of the 30 wounds that showed a decrease in area,
26 had decreased by ≥70% from baseline to week 12. After
12 weeks, the median decrease in wound area was 3.1 cm2
and the mean (SD) was 7.5 (11.2) cm2 (Fig. 2). When a
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Fig. 1. Photographs show wound healing progress after PCMP application. A–C, A venous leg ulcer with a baseline wound area of 19.5 cm2
had been present for 4 months. Previously, the patient underwent compression, debridement, and collagenase treatments. The patient received 11 applications of PCMP. D–F, A surgical wound with baseline wound area of 21.4 cm2 had been present for 1 month. The patient underwent off-loading, debridement, and negative pressure therapy before study participation. The patient received 9 applications of PCMP.

Table 2. Mean Percent Wound Closure from Baseline, by
Wound Type

Wound Type, n (%)
All wounds
Pressure ulcer, 18 (43.9)
Surgical wound, 9 (22.0)
Venous leg ulcer, 5 (12.2)
Diabetic foot ulcer, 4 (9.8)
Ischemic wound, 1 (2.4)
Trauma wound, 1 (2.4)
Graft-versus-host disease
wound, 1 (2.4)
Other, 2 (4.9)

Closure at
Week 4 (%);
n = 41

Closure at
Week 12 (%);
n = 35

37.2
31.6
52.9
44.6
43.2
63.2
93.1
0*

63.1
61.1
84.7
89.3
50.3
60.5
100
70.7

13.4

0†

*The sole graft-versus-host disease wound increased in area from week 0
(84.5 cm2) to week 4 (168 cm2) and then reduced in size to 24.8 cm2 at week 12.
†One patient had a radiation ulcer that decreased in size from 1.2 cm2 at week
0 to 0.6 cm2 at week 4, but had no measurement at week 12. The second patient
had a mixed venous stasis and diabetic neuropathic pressure ulcer that was
76.7 cm2 at week 0, 94.5 cm2 at week 4, and 77 cm2 at week 12.

paired Wilcoxon signed rank test is performed, the wound
area at week 12 was significantly different from baseline
(P < 0.001). Wounds also visibly had an increase in granulation tissue with healing. Five wounds increased in size
from baseline to week 12 due to patient noncompliance.
One participant died during the study period due to
a comorbid condition. No wounds showed signs of complications or infection after 12 weeks, and there were no
reports of adverse events attributable to PCMP.

DISCUSSION

This study of PCMP represents an extensive case series
of a native type I collagen matrix with PHMB antimicrobial
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Fig. 2. Box and whisker plot of change in wound surface area with
PCMP application for wounds of baseline area less than 45 cm2. The
boxes represent the interquartile range, the error bars represent the
range, and the diamonds represent the mean.

for the management of chronic, nonhealing skin wounds.
The application of PCMP appeared to positively impact
the course of wound healing in a variety of complex,
chronic wounds that were unresponsive to prior treatment, and in many cases even resulted in wound closure.
At 12 weeks, most (73.2%) wounds reduced in area
from baseline and many (63.4%) had reached a ≥70% reduction in area. Complete closure was achieved in many
types of wounds, including surgical and trauma wounds,
pressure ulcers, diabetic foot ulcers, and venous leg ulcers. The time to complete wound closure was relatively
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short (6.7 weeks) relative to the duration of the wounds
(103 weeks). An earlier case series with PCMP demonstrated an average time to complete wound closure of 6.8
weeks.36 PCMP was well tolerated, and no systemic or localized adverse events were reported that were attributed to
PCMP. Another case series of 9 wounds treated with PCMP
showed that 6 of the 9 wounds healed in an average of 10
weeks, with the remaining wounds showing improvements
in granulation tissue and a reduction in wound area.37
In recent studies of skin substitutes for the treatment of
wounds, at baseline, venous leg ulcers had a median area
of 6.0–7.5 cm2 and diabetic foot ulcers had a median area
of 3.0–3.9 cm2. The median times to wound closure were
reported as 19.5 weeks for dehydrated human amnion
chorion membrane (dHACM; EpiFix, MiMedx, Marietta,
Ga.), 25 weeks for fetal bovine collagen dressing (Primatrix, Integra Life Sciences, Waltham, Mass.), and 36 weeks
for acellular porcine small intestinal submucosa collagen
dressing (SIS; Oasis, Smith & Nephew, Largo, Fla.).38,39 In
this prospective study of a variety of wound types in which
the median baseline wound area was 7.2 cm2, time to
wound closure with PCMP was 12.9 to 29.4 weeks shorter
than that reported for other skin substitutes, representing a 66% to 82% reduction in time to closure. Similarly,
wound closure rates of other skin substitutes by or at 12
weeks were 32% for dHACM, 27% for fetal bovine collagen dressing, and 14% for SIS.38,39 In this study, PCMP
resulted in a 37% wound closure rate.
Reducing the time to complete wound closure could
substantially reduce the costs associated with chronic
wound management.10 A registry study of nonhealing wounds showed that the cost of unhealed wounds
was $4,000 per patient at 6 months, which increased to
$18,000 per patient at 2 years of wound duration.40 PCMP
treatment appeared to be beneficial for the wound microbial status as well, as none of the chronic wounds in this
study showed signs of infection at week 12.
Native extracellular matrix is a potent inhibitor of proteases, which are implicated in the dysfunctional healing
process of chronic wounds.3,34 Native collagen has been
found to inhibit elastase, resulting in a positive effect on
wound healing.34 In addition, PHMB is a barrier against
microbial colonization and biofilm formation.41 The use
of PCMP appeared to positively affect the number of
wounds with complete closure and the rate of closure
compared with the wound history and other literature,
which could potentially reduce the total cost of wound
care. For example, PCMP may have reduced the need for
other, more expensive, wound healing treatments such
as other skin substitutes, surgical procedures, skin flaps,
or grafts. For those wounds that necessitated further intervention, PCMP assisted in supporting healing and improving granulation tissue. PCMP could also reduce the
number of office visits needed to achieve complete wound
closure, likely reducing associated healthcare costs.
All skin wounds show bacterial colonization, and some
may even progress to active infection of the superficial,
deep dermal, or underlying tissues extending through to
muscle, tendon, capsule, or bone. Persistent, nonhealing
wounds are likely to be deep, large, and poorly vascular-

ized, with significant necrotic tissue, which pose the greatest risk for high bacterial counts and biofilm reformation.
The use of PCMP represents a novel approach for managing bioburden, thus controlling biofilm formation, while
neutralizing destructive enzymes and providing a biocompatible extracellular matrix to support wound closure.
This study included a relatively small number of wounds,
so it is difficult to make conclusive statements about closure
rates or comparisons of closure success for different wound
types. The study involved a variety of wound types and there
were few surgical wounds or pressure wounds examined.
PCMP was also not compared with a control standard-of-care
group. There was no attempt to randomize patients to different treatment arms and the individuals who were assessing
the wound healing were not blinded to the treatment.

CONCLUSIONS

PCMP represents a new class of wound management
tools and is comprised of both native type I collagen and
the antimicrobial PHMB. PCMP appeared to positively impact the management of wound healing across a variety
of complex chronic wounds. Results need to be further
explored and validated with randomized, controlled studies in a larger sample of patients.
Alisha R. Oropallo, MD, FACS, APWCA
Northwell Health Department of Surgery
North Shore/LIJ Comprehensive Wound Care Center
1999 Marcus Avenue, Suite M6
Lake Success, NY 11042
E-mail: aoropallo@northwell.edu
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